Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “The Regents of the University of Colorado, a Body Corporate”

252 pharma patents match "The Regents of the University of Colorado, a Body Corporate" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 252
Index total 30,257
Page 9 / 11

Quick answer

This filtered view shows 252 pharmaceutical patents matching "The Regents of the University of Colorado, a Body Corporate" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

252 results for “The Regents of the University of Colorado, a Body Corporate” · 30,257 patents in full index Clear search

  1. US 9138383

    Nanogel materials and methods of use thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted

  2. US 9091701

    Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis

    The Regents of the University of Colorado, a Body Corporate · Granted Jul 28, 2015 · Expires Jul 23, 2035

    granted

  3. US 9084746

    Therapeutic applications of SMAD7

    The Regents of the University of Colorado, a Body Corporate · Granted Jul 21, 2015 · Expires Jul 16, 2035

    granted

  4. US 9073985

    Methods and products for treating proliferative diseases

    The Regents of the University of Colorado, a Body Corporate · Granted Jul 7, 2015 · Expires Jul 2, 2035

    granted

  5. US 9067968

    Tight junction protein modulators and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Jun 30, 2015 · Expires Jun 25, 2035

    granted

  6. US 9062347

    Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy

    The Regents of the University of Colorado, a Body Corporate · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted

  7. US 9034318

    Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria

    The Regents of the University of Colorado, a Body Corporate · Granted May 19, 2015 · Expires May 14, 2035

    granted

  8. US 9023984

    Diagnostic and therapeutic target for autoimmune diseases and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted May 5, 2015 · Expires Apr 30, 2035

    granted

  9. US 9011844

    Human cystathionine β-synthase variants and methods of production thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 21, 2015 · Expires Apr 16, 2035

    granted

  10. US 8992906

    Compositions and methods for engraftment and increasing survival of adult muscle stem cells

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted

  11. US 8962709

    Resin systems for dental restorative materials and methods using same

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted

  12. US 8957031

    Competitive inhibitors of invariant chain expression and/or ectopic clip binding

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 17, 2015 · Expires Feb 12, 2035

    granted

  13. US 8937046

    Modulating the alternative complement pathway

    The Regents of the University of Colorado, a Body Corporate · Granted Jan 20, 2015 · Expires Jan 15, 2035

    granted

  14. US 8920799

    Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  15. US 8916603

    Methods for treatment with bucindolol based on genetic targeting

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  16. US 8911722

    Modulation of yeast-based immunotherapy products and responses

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 16, 2014 · Expires Dec 11, 2034

    granted

  17. US 8911733

    Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 16, 2014 · Expires Dec 11, 2034

    granted

  18. US 8883189

    Intraocular encapsulation of oxygenic bacteria

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted

  19. US 8883144

    Treatment of pulmonary vascular remodeling with neprilysin

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted

  20. US 8858945

    Three-dimensional structure of complement receptor type 2 and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Oct 14, 2014 · Expires Oct 9, 2034

    granted

  21. US 8840868

    Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted

  22. US 8816046

    Compositions and methods for CaMKII inhibitors and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Aug 26, 2014 · Expires Aug 21, 2034

    granted

  23. US 8808710

    Method of preparing an immunologically-active adjuvant-bound dried vaccine composition

    The Regents of the University of Colorado, a Body Corporate · Granted Aug 19, 2014 · Expires Aug 14, 2034

    granted

  24. US 8735358

    Methods for treating cancer by regulation of tumor necrosis factor-alpha

    The Regents of the University of Colorado, a Body Corporate · Granted May 27, 2014 · Expires May 22, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.